EGFR and non-small cell lung carcinoma: Our study is the first to globally identify the effectors mediating the predicting role of PD-L1 expression in EGFR-mutant advanced NSCLC patients treated with EGFR-TKIs, which explains the inconsistency of the prognostic value of PD-L1 in previous studies.